UnknownPHASE1, PHASE2NCT04112589
A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PETHEMA Foundation
- Principal Investigator
- Pau Montesinos, MDTrial Coordinator, Institution Contact
- Intervention
- Quizartinib(drug)
- Enrollment
- 63 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2019 – 2023
Study locations (20)
- Complexo Hospitalario Universitario A Coruña, A Coruña, Spain
- Hospital General Universitario de Alicante, Alicante, Spain
- Institut Català D'Oncologia-Hospital Germans Trias I Pujol, Badalona, Spain
- Institut Català D'Oncologia-Hospital Duran I Reynals, Bellvitge, Spain
- Hospital Universitario Puerta Del Mar, Cadiz, Spain
- Hospital San Pedro de Alcántara, Cáceres, Spain
- Hospital Universitario Reina Sofía, Córdoba, Spain
- ICO Girona - Hospital Josep Trueta, Girona, Spain
- Hospital Universitario de Jerez de La Frontera, Jerez de la Frontera, Spain
- Complejo Hospitalario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
- Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria, Spain
- Hospital Ramón Y Cajal, Madrid, Spain
- Hospital Universitario 12 de Octubre, Madrid, Spain
- Hospital Universitario Virgen de La Victoria, Málaga, Spain
- Hospital Universitario Central de Asturias, Oviedo, Spain
- +5 more locations on ClinicalTrials.gov
Collaborators
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · Syntax for Science, S.L
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04112589 on ClinicalTrials.govOther trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06303193Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsNational Cancer Institute (NCI)
- RECRUITINGPHASE3NCT07422480A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsTakeda
- RECRUITINGNANCT07500753A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly PatientsThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE4NCT07486713Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRigel Pharmaceuticals
- RECRUITINGPHASE1NCT07107126Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic SyndromesRemedy Plan, Inc.
- RECRUITINGPHASE1NCT07270978Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDSUniversity of Virginia
- RECRUITINGNANCT06781099Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or MyelofibrosisHospices Civils de Lyon
- RECRUITINGPHASE2NCT07228273Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaOHSU Knight Cancer Institute